Health
Health
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced t…
October 21, 2026 · 7:00 AM
Health|Compvide
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 2026
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to su…
October 21, 2026 · 6:47 AM
Health
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfort…
October 21, 2026 · 6:45 AMHealth|OneSpaWorld
OneSpaWorld Announces Third Quarter Fiscal 2026 Financial Results on October 28, 2026
OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, announced today that it will re…
October 21, 2026 · 6:45 AM
Health|Virta Health
Virta Health Reports 37% Greater Weight Loss When GLP-1s are Paired with its AI-enabled Personalized Nutrition
Virta Health, the leader in metabolic disease reversal, today released its 2026 Reversal Report: Metabolic Care in the GLP-1 Era with a striking finding: Virta members taking GLP-1s achieved substantially better results…
October 21, 2026 · 6:17 AM
Health
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bis…
October 21, 2026 · 6:05 AM
Health|Thermo Fisher Scientific
Thermo Fisher Scientific Reports Third Quarter 2026 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2026. Third Quarter Highlights Third quarter revenue grew 9%…
October 21, 2026 · 6:00 AMHealth|Elevance Health
Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
Elevance Health, Inc. (NYSE: ELV) reported third quarter 2026 results ahead of expectations. "Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earning…
October 21, 2026 · 6:00 AM
Health
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor…
October 21, 2026 · 6:00 AM
Health|Vektor Medical
Vektor Medical Completes Enrollment in IMPRoVED-AF Clinical Study and Announces Appointment of Brandon Allen as Senior Vice President of Sales
Vektor Medical, a medical technology company advancing the treatment of cardiac arrhythmias through its non-invasive, AI-based arrhythmia analysis technology, vMap®, today announced the completion of patient enrollment i…
October 21, 2026 · 5:00 AMLatest from leading organizations
Explore recent announcements by organization
